Stephens Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $65
Kymera Therapeutics Price Target Announced at $65.00/Share by Stephens & Co.
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Raises Target Price to $49
Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $49
Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $53
Kymera Therapeutics to Participate in Upcoming November Investor Conferences